Hester Biosciences Q3 FY26: PAT jumps 140%; CEO Rajiv Gandhi re-appointed

Management Changes View source PDF Explain this filing

HESTERBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.2%Reaction day

₹1440.00

prior close

₹1441.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.8%+2.3% vs market

Pharmaceuticals peers, median of 157sector+0.9%+3.2% vs sector

On the reaction day the stock moved 2.3 pts more than Nifty Microcap 250 and 3.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.1

10m

-0.7

15m

+2.0

30m

+2.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.2+1.8+2.3+0.9+3.2

Next day

+4.5+0.5+4.0+0.4+4.2

+4.9+4.3+0.6+2.4+2.5

+6.3+5.6+0.6+2.9+3.4

+4.6+4.6-0.0+2.2+2.4

+4.9+3.8+1.1+2.1+2.8

+7.6+7.5+0.1+4.3+3.3

15d

+8.9+3.8+5.1+1.2+7.7

+7.6-0.3+8.0-0.6+8.3

-12.5-9.6-2.9-10.1-2.4

+12.8+9.9+2.9+3.2+9.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Hester Biosciences approved Q3 FY26 standalone results: revenue up 12% YoY to INR 703.54M, PAT up 140% to INR 106.69M driven by strong Poultry Healthcare (32% growth). Animal Healthcare fell 38% on delayed government orders. Consolidated Q3 revenue rose 22% to INR 774.15M while PAT slipped 18% to INR 93.10M. Standalone 9M PAT grew 16% to INR 257.16M; consolidated 9M PAT rose 50% to INR 409.37M. Board re-appointed founder-promoter Rajiv Gandhi as CEO and MD for 3 years from April 1, 2026, subject to shareholder approval via postal ballot.

Likely market impact

Strong quarterly profit growth and leadership continuity are positive; weak Animal Healthcare and Q3 consolidated PAT decline remain watchpoints.